HOME >> BIOLOGY >> NEWS
A new Twist on bone development

A new research study reveals that formation of the cells that build bone tissue, called osteoblasts, is suppressed by a complicated inhibitory signal and that formation of the skeleton proceeds only after relief of the inhibition. This inhibitory signal is part of normal development, and without it, bone formation proceeds prematurely and abnormally.

A gene called Runx2 is the earliest and most specific indicator of osteoblast formation. However, Runx2 expression precedes the actual appearance of osteoblasts by about 4 days. Dr. Gerard Karsenty from Baylor College of Medicine in Houston, Texas, and colleagues were interested in determining what other regulatory molecules may be involved in this process during the delay period. They focused on proteins called Twist-1 and Twist-2 that are present in decreased amounts in people with Saethre-Chotzen syndrome, a disease characterized by overproduction of bone tissue. The researchers discovered that Twist proteins are found in Runx2-containing cells very early in development and that osteoblast development occurs only after Twist amounts decrease. Further, without Twist proteins, osteoblasts form too early and too much Twist inhibits osteoblast formation but does not influence that amount of Runx2 expression.

The researchers conclude that Twist proteins transiently inhibit osteoblast differentiation during formation of the skeleton by negatively regulating Runx2. According to Dr. Karsenty, "These results reveal an unanticipated complexity in osteoblast differentiation whose initiation is determined by the relief of an inhibition." The researchers went on to identify a novel region of the Twist proteins, named the Twist box, and characterized this region as the specific site required for interaction between the two Twist proteins and Runx2. The authors point out that some Saethre-Chotzen patients have a mutation that results in a loss of the Twist box and that this mutation could easily explain the occurre
'"/>

Contact: Heidi Hardman
hhardman@cell.com
617-397-2879
Cell Press
15-Mar-2004


Page: 1 2

Related biology news :

1. DoubleTwist completes the first annotation of the human genome
2. New Study Offers A Twist On Evolution Of Animal Postures
3. New Twist In Proteins Offers Possible Route To Improved Antibiotics
4. Bronfenbrenner book sums up human development
5. OutFoxed! New research may redefine late-stage cardiac development
6. Disease diagnosis, drug development focus of UH profs biochip research
7. Jefferson Lab detector technology aids development of cystic fibrosis therapy
8. Joslin Diabetes Center launches research section on developmental and stem cell biology
9. LBP-1a gene mutation linked to disruption of normal fetal development
10. Method to visualize gene activity may provide insight into normal development & genome function
11. Wheelchairs biomechanics, prosthetic development

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for ... Approval of this IND allows Sentien to initiate a Phase 1/2 study with ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 11, 2020 , ... ... R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey ... and development. Both Roche and J&J have annual Research and Development spending ...
(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
(Date:7/1/2020)... (PRWEB) , ... June 29, 2020 , ... ... year to date growth of 40% in 2020, despite many obstacles created as ... MedShift aims to increase revenue for its partnered medical practices and medical manufacturers ...
(Date:6/28/2020)... ... 2020 , ... The Indoor Lab, a leading provider of sensor solutions for ... types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using ... will provide a health performance index system that scores all aspects of compliance similar ...
Breaking Biology Technology:
Cached News: